Question · asked by 1 review
Topiramate vs placebo or no treatment: Leaving the study early
- Population
- people with schizophrenia with antipsychotic‐induced weight gain
- Intervention
- Topiramate
- Comparison
- placebo or no treatment
- Outcome
- Leaving the study early
Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Topiramate vs placebo or no treatment Leaving the study early: for any reason · people with schizophrenia with antipsychotic‐induced weight gain Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty). Pharmacological interventions for prevention of weight gain in people with schizophrenia (2022) · Cochrane Headline outcomes only | RR 1.09 [0.85, 1.41] | 2 studies · 132 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.